Current stock page

Catalysts

OCUL Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

OCULOcular Therapeutix, Inc.

Healthcare / Biotechnology

Low Priority

Relative Laggard

BearishEdge 1/10
$6.21−$0.07 (−1.11%)

Latest quote

  • Momentum
    34
  • Value
    41
  • Quality
    42
  • Risk resilience
    36
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 4, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 38/100

Momentum 34/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 27.40%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 34/100AIQ Edge 1/10 Relative Laggard
Beat rate
38%
3 of 8 reported periods
Average surprise
-9.3%
Across covered historical reports
Latest result
-15.5%
Nov 9, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Nov 9, 2026—-$0.36-$0.42-15.5%$14.27M$12.87M
Aug 3, 2026—-$0.40-$0.35+11.5%$13.2M$13.48M
May 5, 2026—-$0.32-$0.41-28.1%$12.72M$10.79M
Feb 5, 2026—-$0.33-$0.29+12.1%$16.13M$13.25M
Nov 4, 2025—-$0.39-$0.37+5.1%$16.14M$14.54M
Aug 5, 2025—-$0.35-$0.39-11.4%$14.57M$13.46M
May 5, 2025—-$0.29-$0.37-27.6%$13.1M$10.63M
Mar 3, 2025—-$0.24-$0.29-20.8%$17.11M$17.08M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
12
Buy
12-month analyst target
$14.00
+125.44% versus current price
Based on 12 analyst observations. Targets are estimates, not predictions.
Low target
$14.00
+125.44% vs latest price
Average target
$14.00
+125.44% vs latest price
High target
$14.00
+125.44% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 4, 2027

Next known earnings or reporting date.

EPS estimate-$0.45

Current analyst expectation for the upcoming report.

Revenue estimate$13.76M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score34

Where event reaction would show up first.

AIQ score38/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
12
Average target
$14.00
Target upside
125.44%
Target range
$14.00 - $14.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
1
Negative
0
gurufocus.com · Nov 9, 2026

Q3 2026 Ocular Therapeutix, Inc. Earnings Call Transcript

Nov 09, 2026 / 01:00PM GMTOperator Good morning, and welcome to the Ocular Therapeutix third quarter 2026 earnings conference call. (Operator Instructions) As a

gurufocus.com · Nov 9, 2026

Ocular Therapeutix (OCUL) Reports Landmark Phase III Results for AXPAXLI in Wet AMD

On November 09, 2026, Ocular Therapeutix Inc (NASDAQ: OCUL) announced significant Phase III clinical trial results for its drug AXPAXLI, targeting wet age-relat

seekingalpha.com · Nov 9, 2026

Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call Transcript

Ocular Therapeutix, Inc. (OCUL) Q3 2026 Earnings Call November 9, 2026 8:00 AM ESTCompany ParticipantsWilliam Slattery - Vice President of Investor...

finance.yahoo.com · Sep 23, 2026

Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?

In the high-stakes realm of clinical-stage biotechnology, long-term shareholder value is fundamentally forged by pipeline assets that solve deep-seated clinical bottlenecks while offering significant pricing power and capital efficiency. Ocular Therapeutix (NASDAQ:OCUL) operates squarely at this intersection, pioneering bioresorbable hydrogel delivery systems designed to fundamentally alter how chronic retinal diseases are treated. The company’s core […]

insidermonkey.com · Sep 3, 2026

Ocular Therapeutix (OCUL): Faster Path To Approval Comes With Rising Costs

On August 3, Ocular Therapeutix (NASDAQ:OCUL) reported second-quarter 2026 financial results that read as much like a regulatory update as an earnings report.

Open full news and sentiment

OCUL Catalysts FAQ

What are the next catalysts for OCUL stock?

OCUL's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move OCUL stock?

Upcoming events that could move OCUL include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could OCUL's next earnings report affect the stock?

OCUL's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive OCUL stock higher?

OCUL could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt OCUL stock?

OCUL could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.